Cost-eff ectiveness of HIV prevention for high-risk groups at scale: An economic evaluation of the avahan programme in south India

The Lancet Global Health

Volumn 2, Issue 9, 2014, Pages e531-e540

  Vassall, Anna ^a   Pickles, Michael ^a,c   Chandrashekar, Sudhashree ^a,b   Boily, Marie Claude ^c   Shetty, Govindraj ^d   Guinness, Lorna ^a   Lowndes, Catherine M ^a,f,g   Bradley, Janet ^e   Moses, Stephen ^d,h   Alary, Michel ^e,g   Reza Paul, Sushena ^e,h   Kumaranayake, Lilani ^a   Blanchard, James ^h   Ramesh, Banadakoppa M ^d,h   Isac, Shajy ^d   Washington, Reynold ^b,d   Watts, Charlotte ^a   Vickerman, Peter ^a,i  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d KARNATAKA HEALTH PROMOTION TRUST   (India)

^e LAVAL UNIVERSITY   (Canada)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITÉ LAVAL   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; COMMUNITY CARE; CONDOM USE; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PROGRAM COST EFFECTIVENESS; PROSTITUTION; QUALITY OF LIFE; SEXUALLY TRANSMITTED DISEASE; PRIORITY JOURNAL;

EID: 84908397709     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70277-3     Document Type: Article

References (32)

1. National AIDS Control Organisation and National Institute of Medical Statistics. New Delhi: Ministry of Health and Family Welfare GoI (2013) Annual Report, 2012-13.
2. Vickerman P, Foss AM, Pickles M, et al. To what extent is the HIV epidemic in southern India driven by commercial sex? A modelling analysis. AIDS 2010; 24: 2563-72.
3. The Bill & Melinda Gates Foundation. Avahan-The India AIDS initiative: the business of HIV prevention and scale. New Delhi: The Bill & Melinda Gates Foundation, 2008.
4. Boily MC, Lowndes CM, Vickerman P, et al. Evaluating large-scale HIV prevention interventions: study design for an integrated mathematical modelling approach. Sex Transm Infect 2007; 83: 582-89.
5. Boily MC, Pickles M, Lowndes CM, et al. Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India. AIDS 2013; 27: 1449-60.
6. Pickles MBM, Vickerman P, Lowndes CM, et al. Assessment of the population-level eff ectiveness of the Avahan HIV-prevention programme in South India: a preplanned, causal-pathway-based modelling analysis. Lancet Glob Health 2013; 1: e289-99.
7. Chandrashekar S, Guinness L, Pickles M, Shetty G, Alary M, Vickerman P, CHARME-1 Evaluation Group, Vassall A. The costs of scaling up HIV prevention for high risk groups: lessons learned from the Avahan programme in India. PLoS One (in press).
8. Galarraga O, Colchero MA, Wamai RG, Bertozzi SM. HIV prevention cost-eff ectiveness: a systematic review. BMC Public Health 2009; 9: S5.
9. Prinja S, Bahugana P, Rudra S, et al. Cost eff ectiveness of targeted HIV prevention interventions for female sex workers in India. Sex Transm Infect 2011; 87: 354-61.
10. Fung IC, Guinness L, Vickerman P, et al. Modelling the impact and cost-eff ectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health 2007; 7: 195.
11. Dandona L, Kumar SG, Kumar GA, Dandona R. Economic analysis of HIV prevention interventions in Andhra Pradesh state of India to inform resource allocation. AIDS 2009; 23: 233-42.
12. Dandona L, Kumar SG, Kumar GA, Dandona R. Cost-eff ectiveness of HIV prevention interventions in Andhra Pradesh state of India. BMC Health Serv Res 2010; 10: 117.
13. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost eff ectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27: 903-17.
14. National AIDS Control Organisation. Annual Technical Report 2011-2012. Delhi: Ministry of Health and Family Welfare, Government of India, 2012.
15. Boerma J, Weir S. Integrating demographic and epidemiological approaches to research on HIV/AIDS: the proximate-determinants framework. J Infect Dis 2005; 191: S61-7.
16. Chandrasekaran P, Dallabetta G, Loo V, et al. Evaluation design for large-scale HIV prevention programmes: the case of Avahan, the India AIDS initiative. AIDS 2008; 22: S1-15.
17. UNAIDS. Costing guidelines for HIV prevention strategies. Geneva: UNAIDS; 2000.
18. Grover G, Shivraj SO. Survival pattern of reported HIV infected individuals in the city of Delhi (India). J Commun Dis 2004; 36: 83-92.
19. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodefi ciency virus disease in southern India. Clin Infect Dis 2003; 36: 79-85.
20. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-43.
21. Gupta I, Trivedi M, Kandamuthan S. Recurrent costs of India's free ART program. In: Haacker M, Claeson M ed. HIV and AIDS in South Asia: an economic development risk. Washington, DC: World Bank, 2009.
22. Creese A, Floyd K, Alban A, Guinness L. Cost-eff ectiveness of HIV/ AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002; 359: 1635-43.
23. Srinivasa Rao ASR, Thomsas K, Kurapati S, Bhat R. Improvement in survival of people living with HIV/AIDS and requirement for 1st- and 2nd-Line ART in India: a mathematical model. Not Am Math Soc 2012; 59: 560-62.
24. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155: 209-16.
25. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-eff ectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21: S117-28.
26. UNAIDS. AIDS at 30: Nations at the Crossroads Geneva; UNAIDS, 2011. http://www.unaids.org/unaids_resources/aidsat30/aids-at-30. pdf (accessed Sept 14, 2012).
27. Reserve Bank of India. Selected Economic Indicators. Reserve Bank of India Bulletin, 2011. http://www.rbi.org.in/scripts/BS_ViewBulletin.aspx?Id=12263 (accessed Aug 5, 2014).
28. International Monetary Fund, 2011. http://elibrary-data.imf.org/DataExplorer.aspx (accessed Aug 5, 2014).
29. Saidel T, Adhikary R, Mainkar M, et al. Baseline integrated behavioural and biological assessment among most at-risk populations in six high-prevalence states of India: design and implementation challenges. AIDS 2008; 22: S17-34.
30. Ramesh BM, Moses S, Washington R, et al. Determinants of HIV prevalence among female sex workers in four south Indian states: analysis of cross-sectional surveys in twenty-three districts. AIDS 2008; 22: S35-44.
31. Lowndes CM, Alary M, Verma S, et al. Assessment of intervention outcome in the absence of baseline data: 'reconstruction' of condom use time trends using retrospective analysis of survey data. Sex Transm Infect 2010; 86: i49-55.
32. Laga M, Vuylsteke B. Evaluating AVAHAN's design, implementation and impact: lessons learned for the HIV prevention community. BMC Public Health 2011; 11: S16.